



# NHCSL

THE NATIONAL HISPANIC CAUCUS OF STATE LEGISLATORS

## EMERGENCY RESOLUTION No. 2026-06

### IgA Nephropathy Awareness Day

Reported to the Caucus by the NHCSL Healthcare Task Force  
Sen. Gustavo Rivera (NY), Chair

**Sponsored by  
Rep. Eva-Dina Delgado (IL) and Sen. Cristina Castro (IL)**

Unanimously approved by the NHCSL Executive Committee on behalf of the entire  
Caucus on April 10, 2026

1 **WHEREAS**, more than 1 in 7 American adults are estimated to have chronic kidney  
2 disease (CKD), yet as many as 9 in 10 American adults with CKD do not know they  
3 have it;<sup>1</sup> and,

4 **WHEREAS**, while the two most common causes of kidney disease are hypertension  
5 and heart disease, the third leading cause of kidney disease is glomerulonephritis,  
6 often caused by rare, immune-mediated kidney diseases such as IgA nephropathy  
7 (IgAN); and,

8 **WHEREAS**, IgAN disproportionately impacts minority populations, with Asian  
9 Americans facing the greatest impact, followed by Hispanic Americans;<sup>2</sup> and,

---

<sup>1</sup> <https://www.cdc.gov/kidney-disease/php/data-research/index.html>

<sup>2</sup> John J. Sim, Qiaoling Chen, Nancy Cannizzaro, Simran K. Bhandari, Ancilla W. Fernandes, John Chang, Cibele Pinto, Asher D. Schachter, Mohit Mathur; [Incidence of Adult Primary Immunoglobulin A](#)

10 **WHEREAS**, patients with glomerular diseases frequently advance to more costly and  
11 more debilitating later stages of kidney disease, including end-stage renal disease  
12 (ESRD), more quickly than patients with CKD in general, with estimates suggesting  
13 that rare kidney diseases make up 5–10 percent of CKD patients but account for  
14 approximately 25 percent of patients receiving treatment kidney failure;<sup>3</sup> and

15 **WHEREAS**, patients often face delays in being diagnosed with IgAN and other  
16 immune-mediated kidney diseases, owing to the difficulty of the rare disease  
17 diagnostic odyssey, the limited number of nephrology providers, and lack of  
18 awareness about the causes of kidney disease; and,

19 **WHEREAS**, kidney disease, including IgAN, presents a significant burden not only on  
20 the health and lives of patients and their families, but also incurs great challenges for  
21 the healthcare system and healthcare costs of states, with estimates suggesting that  
22 patients with IgAN-attributed ESRD have health costs exceeding \$63,000 a year; and,

23 **WHEREAS**, while the federal Medicare program covers the costs of dialysis for many  
24 patients with ESRD, 45 percent of ESRD patients are dually eligible, for Medicare and  
25 Medicaid,<sup>4</sup> and ESRD is a significant source of disability, with ESRD patients  
26 employed at only one-fifth the rate of the general population;<sup>5,6</sup> and,

27 **WHEREAS**, kidney disease patients are entering a new era of hope, including for rare  
28 diseases, with multiple drugs now approved by the Food and Drug Administration to  
29 slow the progression of CKD and multiple drugs approved to slow the progression of  
30 IgAN specifically, including innovative immunology-based therapies, and many more  
31 clinical trials are underway for such products; and,

32 **WHEREAS**, there is growing recognition that early identification of kidney disease  
33 and rare kidney diseases, including through broader screening of patients with low-  
34 cost serum creatinine blood tests and urine albuminuria creatinine ratio tests, can slow  
35 the progression of kidney disease and prevent or delay ESRD,<sup>7</sup> including in patients  
36 with immune-mediated kidney diseases;<sup>8</sup> and,

---

[Nephropathy among a Racially/Ethnically Diverse Population in the United States](#). *Am J Nephrol* 7 April 2025; 56 (2): 172–177.

<sup>3</sup> [Effects of Rare Kidney Diseases on Kidney Failure: A Longitudinal Analysis of the UK National Registry of Rare Kidney Diseases \(RaDaR\) Cohort](#) (shows that RKD is 5-10 percent of CKD in the U.K. but 25 percent of ESRD patients).

<sup>4</sup> <https://www.kidneyfund.org/article/congressional-budget-reconciliation-legislation-and-how-it-could-affect-medicaid>

<sup>5</sup> <https://pmc.ncbi.nlm.nih.gov/articles/PMC5967428/>

<sup>6</sup> <https://www.kidneyfund.org/article/congressional-budget-reconciliation-legislation-and-how-it-could-affect-medicaid>

<sup>7</sup> [https://www.kidneynews.org/view/journals/kidney-news/17/12/article-p13\\_6.xml](https://www.kidneynews.org/view/journals/kidney-news/17/12/article-p13_6.xml)

<sup>8</sup>

[https://journals.lww.com/cjasn/fulltext/2023/11000/a\\_policy\\_call\\_to\\_address\\_rare\\_kidney\\_disease\\_in.2.aspx](https://journals.lww.com/cjasn/fulltext/2023/11000/a_policy_call_to_address_rare_kidney_disease_in.2.aspx)

37 **WHEREAS**, “IgAN Awareness Day” is designated in order to increase awareness  
38 among patients, providers, and policymakers of kidney disease and glomerular  
39 diseases, and IgAN in particular; to support efforts to improve policies that may  
40 increase access to screening, diagnosis, and treatment for kidney disease; and to  
41 provide hope and inspiration to patients, caregivers, and advocates working tirelessly  
42 to advance awareness and better care for kidney disease;

43 **THEREFORE, BE IT RESOLVED**, that the National Hispanic Caucus of State  
44 Legislators calls on states to designate May 14, 2026, as IgAN Awareness Day.

45 IN ITS MEETING OF APRIL 6, 2026, THE NHCSL HEALTHCARE TASK FORCE  
46 UNANIMOUSLY RECOMMENDED THIS RESOLUTION TO THE EXECUTIVE  
47 COMMITTEE FOR APPROVAL AS AN EMERGENCY RESOLUTION.

48 AT THE REQUEST OF THE NHCSL HEALTHCARE TASK FORCE, AND IN ACCORDANCE  
49 WITH THE IMMEDIATE NEEDS PROCEEDS OUTLINED IN THE BYLAWS, THE  
50 EXECUTIVE COMMITTEE UNANIMOUSLY APPROVED THIS RESOLUTION, ON  
51 BEHALF OF THE CAUCUS, ON APRIL 10, 2026, AT ITS MEETING IN NEW YORK, NY.

